In a country which traditionally has been an early adopter of vaccines, and allocates national programme funding based upon cost-effectiveness assessments, it is critical that both post-licensure safety and effective- ness can be assessed comprehensively and in a timely fashion [6]. This will maximise protection of vaccine recipients, confidence in the immunisation programme, and allow appropriate allocation of taxpayer resources. Linkage of national immunisation datasets with health outcome data offers a powerful public health resource.
展开▼